MedTrace Logo

Butyrate in Pediatric Inflammatory Bowel Disease

NCT05456763 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-07-13

No results posted yet for this study

Summary

The first prospective randomised placebo-controlled study in the IBD pediatric population was conducted to evaluate the effectiveness of oral sodium butyrate as add-on therapy in IBD.

Conditions

  • Inflammatory Bowel Diseases

Interventions

DIETARY_SUPPLEMENT

sodium butyrate

add-on therapy irrespective of standard treatment depending on severity (according to the guidelines)

OTHER

placebo

placebo

Sponsors & Collaborators

  • Centre of Postgraduate Medical Education

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2016-02-29
Completion
2022-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05456763 on ClinicalTrials.gov